Literature DB >> 8469009

Survival of patients with carcinoma of the esophagus treated with combined-modality therapy.

W G Wolfe1, A L Vaughn, H F Seigler, J W Hathorn, K A Leopold, F G Duhaylongsod.   

Abstract

Since 1985, 229 cases of carcinoma of the esophagus have been considered for entry into a protocol with the use of preoperative chemotherapy and radiation therapy followed by surgical intervention as the primary element of treatment. One hundred sixty-five patients (93 with adenocarcinoma and 72 with squamous cell carcinoma) had esophagogastrectomy. The 5-year survival of the protocol patients who underwent resection was 25% for both groups--squamous cell carcinoma and adenocarcinoma. Of the protocol patients with squamous cell carcinoma who underwent resection, 40% had a sterilized specimen, whereas of those with adenocarcinoma, 20% had a sterilized specimen. If the patient had a sterilized specimen, the 5-year survival was approximately 60% for adenocarcinoma and 40% for squamous cell carcinoma. Those patients with adenocarcinoma and Barrett's esophagus had a 5-year survival of 55%. Of the patients who underwent only esophagectomy and esophagogastrectomy and had not been entered into the protocol, none lived beyond 3 years. The operative mortality rate for those who had esophagogastrectomy was 5%. Sixty-four patients completed the radiation therapy and chemotherapy but did not undergo surgical procedures because of progressive disease or refusal. Of those patients who completed chemotherapy and radiation therapy without surgical intervention, 5-year survival was 18% in patients with squamous cell carcinoma, whereas no patients with adenocarcinoma survived beyond 3 years. The finding of a sterilized specimen after esophagectomy is a favorable prognostic factor in patients with adenocarcinoma or squamous cell carcinoma. The finding that patients with Barrett's esophagus and adenocarcinoma have an improved chance for survival is perhaps related to an earlier diagnosis. It is clear that some patients with squamous cell carcinoma who did not undergo surgical procedures did have a sterilized specimen, because the survival in this group approached 20% at 5 years.

Entities:  

Mesh:

Year:  1993        PMID: 8469009

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  9 in total

1.  Impact on Radiological and Pathological Response with Neoadjuvant Chemoradiation and Its Effect on Survival in Squamous Cell Carcinoma of Thoracic Esophagus.

Authors:  Abhinav Dewan; S K Sharma; A K Dewan; Ruparna Khurana; Manoj Gupta; Anjali Pahuja; Himanshu Srivastava; Rupal Sinha
Journal:  J Gastrointest Cancer       Date:  2017-03

2.  A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy.

Authors:  B Dunne; J V Reynolds; E Mulligan; A Kelly; M Griffin
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

3.  Field population-based blocking treatment of esophageal epithelia dysplasia.

Authors:  Jun Hou; Pei-Zhong Lin; Zhi-Feng Chen; Zhen-Wei Ding; Shao-Sheng Li; Fan-Shu Men; Li-Ping Guo; Yu-Tong He; Chui-Yun Qiao; Chui-Lan Guo; Jian-Ping Duan; Deng-Gui Wen
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

4.  Serial endoscopic ultrasound in the assessment of response to chemoradiotherapy for carcinoma of the esophagus.

Authors:  D J Bowrey; G W Clark; S A Roberts; A B Hawthorne; T S Maughan; G T Williams; P D Carey
Journal:  J Gastrointest Surg       Date:  1999 Sep-Oct       Impact factor: 3.452

Review 5.  Advanced esophageal carcinoma.

Authors:  T E Lerut; P de Leyn; W Coosemans; D Van Raemdonck; P Cuypers; B Van Cleynenbreughel
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

6.  Endoscopic survey of esophageal cancer in a high-risk area of China.

Authors:  Xu-Jing Lu; Zhi-Feng Chen; Cui-Lan Guo; Shao-Sen Li; Wen-Long Bai; Guo-Liang Jin; Yu-Xia Wang; Fan-Shu Meng; Feng Gao; Jun Hou
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

7.  The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus.

Authors:  F G Duhaylongsod; M R Gottfried; J D Iglehart; A L Vaughn; W G Wolfe
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

8.  Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis.

Authors:  S Thorban; R Rosenberg; R Busch; R J Roder
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

Review 9.  Diagnosis and treatment of esophageal neoplasms.

Authors:  H Kato
Journal:  Jpn J Cancer Res       Date:  1995-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.